FFPE Tissue Histopathology report must accompany the specimen
BRAF Hotspot Mutation Analysis
Test Overview
BRAF Hotspot Mutation Analysis is a molecular diagnostic test used to detect mutations in the BRAF gene, especially the common V600E mutation and other hotspot variants. These mutations are associated with several cancers and help guide targeted therapy decisions.
Why This Test is Done
This test is commonly recommended for:
- Melanoma
- Colorectal cancer
- Thyroid cancer
- Lung cancer
- Hairy cell leukemia
- Brain tumors and other solid tumors
It helps doctors:
- Confirm diagnosis
- Select targeted therapies
- Predict treatment response
- Monitor disease progression
Sample Required
- Tumor Tissue / FFPE Block / Slides
OR
- Peripheral Blood / Plasma (depending on clinical indication)
Methodology
- Real-Time PCR / PCR-Based Mutation Detection / NGS (as applicable)
Mutations Commonly Analyzed
- BRAF V600E
- BRAF V600K
- Other hotspot mutations in exon 15
Preparation
- No special preparation required.
- Clinical history and pathology report may be needed.
Turnaround Time
- Approximately 5–10 working days
Interpretation
Positive Result
- Indicates presence of BRAF mutation.
- May suggest eligibility for BRAF-targeted therapy.
Negative Result
- No detectable hotspot mutation identified in tested regions.
Clinical Significance
Detection of BRAF mutations plays an important role in:
- Precision oncology
- Personalized treatment planning
- Prognostic assessment
Disclaimer
Results should be interpreted along with clinical findings, histopathology, and other laboratory investigations by a qualified healthcare professional.
